WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today provided an update on its clinical trials with three compounds: ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase; ARQ 501, a first-generation Activated Checkpoint TherapySM (ACT) candidate; and ARQ 171, a second generation ACT compound.